Skip to main content
Top
Published in: Journal of Cachexia, Sarcopenia and Muscle 2/2011

Open Access 01-06-2011 | Original Article

Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease

Authors: Mitja Lainscak, Stephan von Haehling, Wolfram Doehner, Irena Sarc, Tina Jeric, Kristina Ziherl, Mitja Kosnik, Stefan D. Anker, Stanislav Suskovic

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 2/2011

Login to get access

Abstract

Background

Nutritional status, weight loss and cachexia have important prognostic implications in patients with chronic obstructive pulmonary disease (COPD). Body mass index (BMI) has been implicated in COPD risk assessment, but information is mostly limited to composite scores or to patients with stable disease. We aimed to analyse the association between BMI and mortality in acute exacerbation of COPD.

Methods

This retrospective survey included 968 patients hospitalized due to acute exacerbation of COPD at the University Clinic Golnik from February 2002 to June 2007. Vital status was ascertained with Central Population Registry, and database was censored on November 1, 2008.

Results

Median BMI was 25.08 kg/m2 (interquartile range, 21.55–29.05 kg/m2) and 210 patients (22%) had BMI < 21 kg/m2. During median follow-up of 3.26 years (1.79–4.76 years), 430 patients (44%) died. Lowest mortality was found for BMI 25.09–29.05 kg/m2. When divided per BMI decile, mortality was lowest for BMI 25.09–26.56 kg/m2 (33%). In univariate analysis, BMI per quartile and BMI per unit increase were predictive for all-cause mortality. In an adjusted model, BMI per 1 kg/m2 unit increase was associated with 5% less chance of death (hazard ratio 0.95, 95% confidence interval 0.93–0.97).

Conclusions

Low BMI < 21 kg/m2 is frequent in patients hospitalized due to acute exacerbation of COPD. Higher BMI was independently predictive of better long-term survival. A better outcome in obese patients compared to normal weight is in contrast to primary prevention data but concurs with observations of an obesity paradox in other cardiovascular diseases.
Literature
1.
go back to reference von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010;1:1–5.CrossRef
2.
go back to reference Doehner W, von Haehling S, Anker SD, Lainscak M. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr. 2009;121:293–6.PubMedCrossRef Doehner W, von Haehling S, Anker SD, Lainscak M. Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin Wochenschr. 2009;121:293–6.PubMedCrossRef
3.
go back to reference Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.PubMed Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.PubMed
4.
go back to reference Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9:29–35.PubMedCrossRef Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJ, et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 2003;9:29–35.PubMedCrossRef
5.
go back to reference Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543–54.PubMed Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543–54.PubMed
6.
go back to reference Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007;10:433–42.PubMedCrossRef
7.
go back to reference Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31:492–501.PubMedCrossRef Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31:492–501.PubMedCrossRef
8.
go back to reference Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.PubMed Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.PubMed
9.
go back to reference Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–67.PubMedCrossRef Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459–67.PubMedCrossRef
10.
go back to reference Connors Jr AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959–67.PubMed Connors Jr AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959–67.PubMed
11.
go back to reference Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234–41.PubMedCrossRef Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234–41.PubMedCrossRef
12.
go back to reference Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med. 2007;101:954–1960.CrossRef Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T, Lindberg E, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med. 2007;101:954–1960.CrossRef
13.
go back to reference Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med. 2009;24:1043–8.PubMedCrossRef Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med. 2009;24:1043–8.PubMedCrossRef
14.
go back to reference Ranieri P, Bianchetti A, Margiotta A, Virgillo A, Clini EM, Trabucchi M. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc. 2008;56:909–13.PubMedCrossRef Ranieri P, Bianchetti A, Margiotta A, Virgillo A, Clini EM, Trabucchi M. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc. 2008;56:909–13.PubMedCrossRef
16.
go back to reference Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82:53–9.PubMed Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82:53–9.PubMed
17.
go back to reference Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010;1:9–21.CrossRef Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2010;1:9–21.CrossRef
18.
go back to reference Segurola H, Pérez-Portabella C, Ferrer J, Hermosilla E, Planas M, Burgos R. Muscle wasting in patients with chronic obstructive pulmonary disease (COPD). J Cachexia Sarcopenia Muscle. 2010;1:47 (Abstract 009). Segurola H, Pérez-Portabella C, Ferrer J, Hermosilla E, Planas M, Burgos R. Muscle wasting in patients with chronic obstructive pulmonary disease (COPD). J Cachexia Sarcopenia Muscle. 2010;1:47 (Abstract 009).
19.
go back to reference Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8E–10E.PubMedCrossRef Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol. 2008;101:8E–10E.PubMedCrossRef
20.
go back to reference Lainscak M, Majc Hodoscek L, Düngen HD, Rauchhaus M, Doehner W, Anker SD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr. 2009;121:309–13.PubMedCrossRef Lainscak M, Majc Hodoscek L, Düngen HD, Rauchhaus M, Doehner W, Anker SD, et al. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr. 2009;121:309–13.PubMedCrossRef
21.
go back to reference Lainscak M, Andreas S, Scanlon PD, Somers VK, Anker SD. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med. 2006;45:837.PubMedCrossRef Lainscak M, Andreas S, Scanlon PD, Somers VK, Anker SD. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med. 2006;45:837.PubMedCrossRef
22.
go back to reference Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic obstructive pulmonary disease—association to cachexia and hormonal derangement. Int J Cardiol. 2007;119:83–9.PubMedCrossRef Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic obstructive pulmonary disease—association to cachexia and hormonal derangement. Int J Cardiol. 2007;119:83–9.PubMedCrossRef
23.
go back to reference Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.PubMedCrossRef Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.PubMedCrossRef
24.
go back to reference Farkas J, Kosnik M, Zaletel-Kragelj L, Flezar M, Suskovic S, Lainscak M. Distribution of self-rated health and association with clinical parameters in patients with chronic obstructive pulmonary disease. Wien Klin Wochenschr. 2009;121:297–302.PubMedCrossRef Farkas J, Kosnik M, Zaletel-Kragelj L, Flezar M, Suskovic S, Lainscak M. Distribution of self-rated health and association with clinical parameters in patients with chronic obstructive pulmonary disease. Wien Klin Wochenschr. 2009;121:297–302.PubMedCrossRef
25.
go back to reference Farkas J, Kosnik M, Flezar M, Suskovic S, Lainscak M. Self-rated health predicts acute exacerbations and hospitalisations in patients with COPD. Chest. 2010;138:323–30.PubMedCrossRef Farkas J, Kosnik M, Flezar M, Suskovic S, Lainscak M. Self-rated health predicts acute exacerbations and hospitalisations in patients with COPD. Chest. 2010;138:323–30.PubMedCrossRef
26.
go back to reference Imai K, Gregg EW, Chen YJ, Zhang P, de Rekeneire N, Williamson DF. The association of BMI with functional status and self-rated health in US adults. Obesity. 2008;16:402–8.PubMedCrossRef Imai K, Gregg EW, Chen YJ, Zhang P, de Rekeneire N, Williamson DF. The association of BMI with functional status and self-rated health in US adults. Obesity. 2008;16:402–8.PubMedCrossRef
27.
go back to reference Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009;103:1461–7.PubMedCrossRef Schembri S, Anderson W, Morant S, Winter J, Thompson P, Pettitt D, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009;103:1461–7.PubMedCrossRef
28.
go back to reference Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM. 2010;103:817–29.PubMedCrossRef Steer J, Gibson GJ, Bourke SC. Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM. 2010;103:817–29.PubMedCrossRef
29.
go back to reference Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–67.PubMedCrossRef Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–67.PubMedCrossRef
30.
go back to reference van Hees HWH, Linkels M, Pigmans CJC, Dekhuijzen PNR, Heunks LMA. Akt activation is not reduced in the diaphragm of emphysematous hamsters. J Cachexia Sarcopenia Muscle. 2010;1:65 (Abstract: 049). van Hees HWH, Linkels M, Pigmans CJC, Dekhuijzen PNR, Heunks LMA. Akt activation is not reduced in the diaphragm of emphysematous hamsters. J Cachexia Sarcopenia Muscle. 2010;1:65 (Abstract: 049).
31.
go back to reference Kamiide Y, Sugiyama M, Tamaki C, Matsuo T, Takagi H, Furuya M. Effect of SUN11031 (a synthetic human ghrelin) on pulmonary and systemic abnormalities in the cigarette smoke-induced chronic obstructive pulmonary disease (COPD) model. J Cachexia Sarcopenia Muscle. 2010;1:67 (Abstract: 056). Kamiide Y, Sugiyama M, Tamaki C, Matsuo T, Takagi H, Furuya M. Effect of SUN11031 (a synthetic human ghrelin) on pulmonary and systemic abnormalities in the cigarette smoke-induced chronic obstructive pulmonary disease (COPD) model. J Cachexia Sarcopenia Muscle. 2010;1:67 (Abstract: 056).
32.
go back to reference Gertner JM, Oo C. Performance improvement in chronic obstructive pulmonary disease (COPD) cachexia with SUN11031 (a synthetic human ghrelin) in a placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2010;1:100 (Abstract: 128). Gertner JM, Oo C. Performance improvement in chronic obstructive pulmonary disease (COPD) cachexia with SUN11031 (a synthetic human ghrelin) in a placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2010;1:100 (Abstract: 128).
33.
go back to reference Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef
34.
go back to reference Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.PubMedCrossRef Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.PubMedCrossRef
35.
go back to reference Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301–5.PubMedCrossRef Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63:301–5.PubMedCrossRef
36.
go back to reference Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008;63:194–200.PubMedCrossRef Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008;63:194–200.PubMedCrossRef
37.
go back to reference van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010;11:179–87.PubMedCrossRef van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc. 2010;11:179–87.PubMedCrossRef
39.
go back to reference von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.CrossRef von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.CrossRef
Metadata
Title
Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease
Authors
Mitja Lainscak
Stephan von Haehling
Wolfram Doehner
Irena Sarc
Tina Jeric
Kristina Ziherl
Mitja Kosnik
Stefan D. Anker
Stanislav Suskovic
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 2/2011
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-011-0023-9

Other articles of this Issue 2/2011

Journal of Cachexia, Sarcopenia and Muscle 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine